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Abstract
Background and Purpose—Efforts to reduce disparities in recurrent stroke among Black and 
Latino stroke survivors have met with limited success. We aimed to determine the effect of peer 
education on secondary stroke prevention amongst predominantly minority stroke survivors.
Methods—Between 2009 and 2012, we enrolled 600 stroke or transient ischemic attack 
survivors from diverse, low-income communities in New York City into a 2-arm randomized 
clinical trial that compared a 6 week (1 session/week) peer-led, community-based, stroke 
prevention self-management group workshop (N=301) to a wait-list control group (N=299). The 
primary outcome was the proportion with a composite of controlled blood pressure (<140/90 
mmHg), low density lipoprotein (LDL) cholesterol < 100 mg/dL, and use of antithrombotic 
medications at 6 months. Secondary outcomes included control of the individual stroke risk 
factors. All analyses were by intent-to-treat.
Results—There was no difference in the proportion of intervention and control group 
participants’ achieving the composite outcome (34% versus 34%, p=0.98). The proportion with 
controlled blood pressure at 6 months was greater in the intervention group than in the control 
group (76% versus 67%; p=0.02). This corresponded to a greater change in systolic blood pressure 
in the intervention versus control group (−3.63 SD 19.81 mm Hg versus +0.34 SD 23.76 mmHg; 
p=0.04). There were no group differences in the control of cholesterol or use of antithrombotics.
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Conclusions—A low-cost peer education self-management workshop modestly improved blood 
pressure, but not LDL cholesterol or antithrombotic use, among stroke and TIA survivors from 
vulnerable, predominantly minority urban communities.
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Stroke is the fourth leading cause of mortality and a leading cause of disability in the United 
States (US).1 Over the next two decades, the proportion of the US population with a history 
of stroke is expected to rise to close to 4% and stroke-associated healthcare costs are 
expected to increase by 129%.2 There are also long-standing disparities in the incidence of 
stroke and TIA in minority populations in the US.3–7 Although stroke-related mortality has 
steadily declined in the US since the 1950s, stroke death rates have remained higher in 
blacks than in whites.1 Minority groups are also at greater risk for recurrent stroke. Two 
studies, including one in Northern Manhattan, found a two to three-fold increased risk for 
recurrent stroke among African Americans and Latinos relative to whites.89
A prior history of a stroke or transient ischemic attack (TIA) represents the strongest risk 
marker for future stroke.8, 10–12 Three of the most important actions stroke and TIA 
survivors can take to reduce their risk of future strokes include controlling blood pressure to 
a goal of less than 140/90 mmHg,13 controlling cholesterol to a goal low density lipoprotein 
(LDL) of less than 100 mg/dL,14, 15 and – unless the stroke represents a hemorrhagic event – 
taking an antithrombotic medication.16, 17 Yet, control of these stroke prevention measures 
among stroke and TIA survivors remains suboptimal, particularly among individuals from 
minority groups.18–22 Accordingly, differences in the control of these stroke risk factors 
likely explain, at least in part, disparities in prognosis in stroke and TIA survivors.
Given the increasing burden of stroke in the US and the heightened risk of stroke among 
stroke and TIA survivors from minority groups, there is a pressing need to develop 
interventions that improve stroke risk factors, particularly among individuals from 
historically disadvantaged groups such as Latinos and African Americans in the United 
States. Evidence suggests that self-management education is a promising approach to 
improving outcomes for individuals in these populations.23–25 Some of these programs 
employ peer educators or community health workers who are trusted and respected members 
of the community, culturally and linguistically compatible with the target population, and 
hence, well suited to facilitating social support, education, access, adherence, and promotion 
of self-care.26–28 The provision of peer education in a group-based format with stroke/TIA 
survivors from one’s community may be conducive to a supportive environment that 
enhances the effectiveness of peer education.
Accordingly, we employed a community-based participatory research approach29 to develop 
a culturally-tailored, peer-led stroke prevention group-based workshop adapted from the 
Chronic Disease Self Management Program.30 The primary goal was to determine whether 
participation in such a workshop could increase the proportion of stroke and TIA survivors 
who achieve a composite outcome of control of blood pressure (<140/90 mm Hg), lipids 
(LDL cholesterol <100 mg/dL), and regular use of anti-thrombotic medications. Secondary 
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outcomes of interest included control of the individual stroke prevention measures, change 
in blood pressure and LDL cholesterol assessed as continuous variables, medication 
adherence, and depressive symptoms.
Methods
Study Population
Between June 2009 and January 2012, our community-academic team recruited individuals 
with a history of stroke or TIA through screenings at senior centers, churches, and health 
fairs; contacting patients with a history of a stroke on hospital registries of an academic 
medical center, a federally-funded community health center, and a home care nursing 
program; and advertising the study in clinics, community organizations, and newspapers 
based in the Upper Manhattan and South Bronx neighborhoods of New York City. 
Participants were eligible if they were at least 40 years of age and if they reported the 
occurrence of a stroke or “mini-stroke” (i.e., TIA) within the past 5 years. Participants were 
excluded if they did not have capacity to provide informed consent, if they did not have the 
physical or mental capacity to participate meaningfully in self-management workshops (e.g., 
severe aphasia or cognitive impairment), if they were non-English- and non-Spanish-
speaking, or if they resided in an institutionalized setting. The local institutional review 
board approved the study, and all participants provided written informed consent. Additional 
details about the Prevent Recurrence of All Inner-City Strokes through Education (PRAISE) 
trial study methods have been published elsewhere.30
Study Design
The study was a 2-arm randomized controlled trial with a 6-month follow-up. After in-
person enrollment and baseline assessment, participants returned for an in-person interview 
at 6-months to determine study outcomes.
Baseline Assessments
At baseline, research assistants confirmed each participant’s eligibility, assessed their 
demographic status, reviewed medication lists, surveyed medical problems to obtain a 
Charlson Comorbidity Index31, and assessed stroke-related disability using the Modified 
Rankin Scale.32 Trained study personnel also administered validated self-report measures of 
depressive symptoms and medication adherence, measured blood pressure, and collected 
blood to measure LDL cholesterol. Participants brought medication bottles to provide 
prescription information.
Randomization
After completion of baseline assessments, research assistants allocated participants to a 
randomly selected group. Randomization was generated by a computerized random-number 
sequence in blocks of two, four, or six people. Participant assignments were placed in 
sealed, opaque envelopes by a third party who had no contact with participants. 
Randomization was stratified by recruitment approach; those recruited from community-
based, academic medical center, community health center, and the homecare nursing agency 
were randomized separately.
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Peer Education Intervention Group—Participants randomized to the peer education 
intervention group were scheduled to attend a weekly peer-led workshop for six weeks with 
each session scheduled for ninety minutes. The workshop was modeled on the Chronic 
Disease Self-Management Program in which participants learn and practice self-
management skills in a supportive group environment.25, 33 The workshop was comprised of 
didactic components that 1) explained the biology of stroke and stroke treatments in terms 
lay people could understand; 2) stressed the importance of adherence to preventive 
medications to reduce stroke recurrence; and 3) provided suggestions for optimizing 
medication adherence and working with a healthcare team. Sessions took place in groups of 
eight to ten participants in either English or Spanish and were led by two peer leaders with 
similar socioeconomic backgrounds and health problems as the participants. Participants 
could bring a family member, friend, or home attendant if they chose. At the end of each 
session, participants were asked to make an “action plan” which specified a concrete step 
they could take to help prevent a recurrent stroke. They were encouraged to choose 
something relevant to what they had learned during that week’s session. Subsequent sessions 
would begin with participants reporting back to the group on the results of their efforts to 
implement this action plan. Hence, key ingredients of the peer education intervention 
workshop included modeling of self-management and problem-solving techniques, guidance 
for self-management, weekly action planning for specific behaviors, feedback on progress, 
and social persuasion through group support. At the randomization visit, participants in the 
intervention group additionally received a small packet of culturally-sensitive stroke 
education materials and a list of local health providers, including those that accepted patients 
without health insurance. Participants also received their baseline results pertaining to their 
blood pressure and LDL cholesterol in writing and were encouraged to discuss these results 
with their health care provider.
Wait-List Control Group—Participants in the wait-list control group were told they 
would receive access to the peer education workshops at no cost after a one-year waiting 
period. At the randomization visit, they received the same small packet of stroke education 
materials, list of local health providers, and advice to discuss blood pressure and cholesterol 
results with their health care providers as participants in the intervention group.
Follow-Up Assessments
Six months after randomization, participants in both groups returned for in-person follow-up 
assessments. Data collection at the 6-month study visit was similar to the baseline visit. 
Research assistants who performed follow-up assessments were blinded to group 
assignment.
Outcomes and Measurements
The primary outcome was the proportion of participants who achieved goals for all three key 
stroke prevention measures - blood pressure (<140/90 mmHg), LDL cholesterol <100 
mg/dL, and antithrombotic use at 6 months. Key secondary outcomes included the 
proportion with control of blood pressure, LDL cholesterol, and antithrombotic use, as 
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individual prevention measures, as well as change in within-participant systolic and diastolic 
blood pressure, and change in within-participant LDL cholesterol; change in the proportion 
with good self-reported medication adherence between baseline and 6 months; and change 
in the proportion with elevated depressive symptoms between baseline and 6 months.
Trained research assistants measured blood pressure using a BP Tru automatic 
sphygomanometer according to the American Heart Association guidelines.34 The average 
of the last two of three readings was used for analyses. LDL cholesterol was measured using 
the direct method, eliminating the need for fasting.35 Use of anti-thrombotic medication was 
assessed by a review of medication bottles during the baseline visit or by asking patients to 
read the names of all their pill bottles at home by telephone. Consistent with the recent 
recommendations of the American Heart Association/American Stroke Association 
guidelines16, participants were considered to be using an appropriate antithrombotic 
medication if they took aspirin (greater than 50mg per day at least three days per week), 
clopidogrel, or the combination of aspirin and dipyridamole as antiplatelet therapy, or 
anticoagulation with warfarin or equivalent for patients with atrial fibrillation and had no 
contraindication to antiplatelet and anticoagulant medication. We measured medication 
adherence using the Morisky Medication Adherence Scale,36 which includes eight items that 
assess pill-taking behaviors. Summary scores on the scale can classify individuals into non-
adherent (<6 points) and adherent (6 to 8 points) groups and these categorizations are 
concordant with a pharmacy refill measure of medication adherence.37 The team measured 
depressive symptoms using the 8-item version of the Patient Health Questionnaire,38 a well-
validated measure of depressive symptoms in racially and ethnically diverse patients39 
which has been validated in stroke survivors.40 A score of 10 or higher has a sensitivity of 
91% and specificity of 89% for diagnosing depression in stroke survivors. The 8-item 
version is identical to the 9-item version except it omits one item asking about suicidal 
ideations.41
Statistical Analysis
We evaluated differences between participants randomized to the intervention and control 
groups using t-tests for continuous variables and chi-square analysis for categorical 
variables. We used intent-to-treat analyses to compare participants on all key outcomes. As a 
sensitivity analysis, we used generalized estimating equations (GEE) to compare the 
likelihood of achieving the composite outcome and the individual stroke prevention 
measures at 6-months in the intervention group as compared to the control group after 
accounting for control status at baseline, We used mixed-models to compare the change in 
blood pressure and change in lipids between baseline and 6 months between patients in the 
intervention and control groups. Missing values were imputed using multiple imputation 
under the assumption that values were missing at random. As our findings were similar 
when we performed analyses with and without imputing missing values, we only present 
data pertaining to our imputed data. We additionally performed exploratory, (i.e., not pre-
specified) subgroup analyses for the effect of the intervention on blood pressure by sex and 
race/ethnicity, and tested for significance using a treatment*subgroup interaction test.
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Sample size was calculated for the composite outcome of combined control of blood 
pressure, LDL cholesterol, and antithrombotic use. Based on prior literature,20 we used a 
conservative estimate of baseline use of stroke prevention measures (40%) for our sample 
size estimate. With 80% power, 5% significance level, and a two-tailed test, we estimated 
we would need 270 participants per group to detect a 20% relative difference in the 
proportion of participants in the intervention group who achieved the composite outcome as 
compared to the proportion achieving the composite outcome in the control group (i.e., 70% 
in intervention arm versus 56% in control arm). To account for loss to follow-up, we 
increased the sample size to 600. All analyses were conducted based on the intention-to-treat 
principle. PASS (version 08.0.13, NCSS, LLC, Keysville, UT) was used for sample size 
calculation and SAS 9.2 software (SAS Institute Inc., Cary, NC) was used for all other 
analyses.
Results
Of 2,665 individuals who were screened for study participation, 52% were ineligible, 24% 
declined, and 600 enrolled and were randomized (301 intervention; 299 control) (Figure). 
We retained 85% at 6 month follow up. There were no significant differences in key 
sociodemographic or clinical characteristics between participants who did and did not 
complete follow-up.
Participants randomized to the intervention and control groups were similar in demographic 
and clinical variables at baseline (Table 1). The mean (SD) age of participants was 63 (11) 
years, 59% were women, 86% were non-white, 57% had an annual household income of less 
than $15,000, and nearly one-third had a less than high school education. Approximately 
one-third had blood pressure above goal, 42% had LDL cholesterol above goal, 18% were 
not taking an antithrombotic medication, and only 35% were at goal for all three stroke 
prevention measures. Forty percent reported nonadherence to medications. Among 
participants randomized to the intervention, the mean number of workshop sessions attended 
was four. Seventy-one percent attended at least 50% of the scheduled sessions, and 16% did 
not attend any sessions.
There was no difference in the proportion of intervention and control participants who at 6 
months had attained all three stroke prevention measures (34% versus 34%, p=0.98). 
Furthermore, there were no differences in the proportion of intervention and control 
participants who at 6 months had controlled LDL cholesterol (54% versus 58%, p=0.46) or 
who took an anti-thrombotic medication (82% versus 84%, p=0.61). A higher proportion of 
participants randomized to the intervention had controlled blood pressure at 6 months as 
compared to control participants (76% versus 67%; p=0.02; Table 2). This corresponded to 
1.13 times (95% CI: 1.02–1.25) increased likelihood of having controlled blood pressure at 
6 months if assigned to the intervention compared to the control group. In the sensitivity 
analysis that controlled for baseline blood pressure control status, the difference in blood 
pressure control status at 6 months attributable to the intervention was nearly statistically 
significant (p=0.07). Participants in the intervention group had a greater change in systolic 
blood pressure at 6 months than control participants (−3.63 SD 19.81 mm Hg versus +0.34 
SD 23.76 mmHg, p=0.04), but no significant difference in diastolic blood pressure (−1.95 
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SD 10.26 mm Hg versus −0.63 SD 11.88 mm Hg; p=0.18). The proportion of participants 
who were adherent increased by 7.4% in the intervention group compared with 1.0% in the 
control group (p=0.16). The proportion who were depressed declined by 10.5% in the 
intervention group compared with 5.7% in the control group (p=0.16). There were no 
significant interactions between the effect of the intervention and either sex or race/ethnicity.
Discussion
In this study, participants randomized to a peer led community-based stroke education 
workshop as compared to a wait-list control group did not achieve greater combined control 
of three key stroke prevention measures, nor did they improve their control of LDL 
cholesterol or antithrombotic use when these stroke prevention measures were examined 
individually. A greater proportion of stroke and TIA survivors randomized to the 
intervention did, however, achieve controlled blood pressure, and this was associated with a 
group difference in systolic blood pressure of approximately 4 mm Hg. The intervention was 
also associated with a trend toward an improvement in medication adherence and 
depression.
Controlling blood pressure remains the cornerstone of the prevention of recurrent 
stroke.17, 42 A meta-analysis of the effects of antihypertensive medications showed that a 
reduction in systolic blood pressure of 5 mm Hg was associated with a 20% reduction in 
stroke.43 Although the optimal target blood pressure for stroke survivors is still being 
explored, reductions in blood pressure have been associated with lower rates of stroke even 
among stroke survivors with controlled blood pressure.43, 44 To put our intervention in 
perspective, a recent Cochrane meta-analysis of interventions to improve modifiable risk 
factors in stroke survivors found that there were no significant benefits of organizational, 
educational, or behavioral interventions on risk factor control.45 Accordingly, this peer led 
approach to improving stroke outcomes may be welcomed as a means of improving stroke 
outcomes, particularly in vulnerable communities with a high proportion of low-income 
minorities.
In contrast, with blood pressure control, achieving LDL cholesterol goals below 100 mg/dL 
was a class B recommendation according to the American Stroke Association guidelines at 
the time the study was conducted,17 and the newest guidelines for managing cholesterol 
suggest that use of statins might be a more important target for stroke prevention than LDL 
number in future studies.46 As LDL cholesterol is largely dependent on prescribing practices 
of clinicians, clinical uncertainty about the importance of LDL cholesterol goals may have 
limited the impact of this patient intervention on this goal. With respect to antithrombotic 
use, over 80% of participants in both groups were taking antithrombotics at baseline. As 
participants were, in part, enrolled from non-medical settings, we did not have access to 
medical records, and could not ascertain the type of stroke (hemorrhagic versus ischemic) 
nor the proportion with an indication for antithrombotic medication for stroke prophylaxis. 
In population-based samples, about 10% of stroke survivors have contraindications to 
antithrombotics. Hence, we may have been unable to demonstrate an effect of our 
intervention on this stroke prevention measure due to ceiling effects.
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There were several notable strengths of this study. In partnership with our community action 
board, we successfully recruited a group of stroke and TIA survivors who are often excluded 
from clinical trials.47 Many of our participants were non-white, had incomes below the 
poverty level, lacked health insurance, and had significant levels of disability and distress as 
measured by the modified Rankin score and the PHQ, respectively. Despite these 
vulnerabilities, the majority of participants attended more than half of the workshop 
sessions, confirming that such an approach is feasible, even among low-income, minority 
stroke survivors. This community-based, peer led intervention has the potential to be more 
easily sustained in the low-income, non-white communities at highest risk for stroke as 
opposed to other more resource-intensive strategies such as individualized case-management 
or tailored health education that involve significant time and effort by health care 
professionals.45
The study also had several limitations. The generalizability of our findings to other stroke 
and TIA survivor populations remains unknown. Recruitment required substantial effort and 
led to the inclusion of many participants already reaching study goals for stroke prevention. 
The optimal approach to identifying participants for such an intervention would benefit from 
careful consideration. For example, limiting recruitment to stroke centers or TIA clinics may 
facilitate a more targeted approach but may exclude the large number of stroke/TIA 
survivors who do not follow at such centers. We did not utilize an attention control group, 
and thus, it is difficult to determine which aspects of the intervention were most important 
for achieving the improvement in blood pressure control. Future studies could assess the 
extent to which the use of peer educators is a key component of chronic disease self-
management interventions, particularly in minority populations. The provision of an 
educational packet to participants in the wait-list control group may have contributed to a 
contamination bias that would have biased our results to the null. We did not assess the 
extent to which blinding was maintained among research assistants performing outcomes 
assessments. Our measure of medication adherence was based on self-report and was not 
specific to stroke medications. Future studies could examine the impact of the intervention 
on objective measures of adherence to stroke prevention medications to determine the extent 
to which such approaches lead to better risk factor control through increased medication or 
lifestyle adherence or through empowering patients to be proactive when visiting their 
clinicians.
In summary, a peer education workshop can be successfully delivered to stroke and TIA 
survivors in vulnerable communities and can produce modest improvements in blood 
pressure control. Given the strong association between blood pressure and stroke risk, this 
peer led approach may be helpful for reducing disparities in stroke outcomes. Future studies 
should assess the effect of targeting this type of intervention to stroke/TIA survivors who are 
not reaching goals for stroke prevention.
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CONSORT (Consolidated Standards of Reporting Trials) Diagram of the Prevent 
Recurrence of All Inner-City Strokes through Education (PRAISE) trial
Abbreviations: TIA, transient ischemic attack
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  Age, mean (SD), y 63 ± 11 64 (11) 0.59
  Female, % 60 59 0.82
  Race or ethnicity, % 0.39
     Black 40 43
     Latino 42 37
     White 13 14
     Other 4 6
  Annual income ≤ $15,000, % 56 58 0.62
  Less than high school education, % 31 30 0.98
  Insurance 0.97
     Medicaid, % 29 30
     Medicare, % 39 40
     Commercial, % 26 24
     Uninsured % 6 6
Clinical
  Years since last stroke or TIA, mean (SD) 1.8 (1.4) 1.8 (1.5) 0.79
  Systolic BP, mean (SD), mm Hg 131 (22) 132 (22) 0.59
  Diastolic BP, mean (SD), mm Hg 78 (12) 78 (12) 0.46
  Use antihypertensive medication, % 78 83 0.11
  LDL cholesterol, mean (SD) 97 (38) 97 (35) 0.80
  Use of anti-lipid medication, % 65 63 0.63
  Charlson Co-morbidity Index, mean ± SD 3.7 (2.1) 3.6 (2.1) 0.44
  Modified Rankin Score 3 or 4, % 48 46 0.59
  Depressed (PHQ score ≥10), % 31 28 0.39
  Nonadherent to medications, % 42 38 0.41
Abbreviations: BP, blood pressure; LDL, low-density lipoprotein; TIA, transient ischemic attack; PHQ, Patient Health Questionnaire-8 item 
version
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Control of 3 stroke prevention measures at 0 mo, % 37 33 1.09 (0.88 – 1.36) 0.43
Control of 3 stroke prevention measures at 6 mo, % 34 34 1.00 (0.80 – 1.25) 0.98
Change in % with control of 3 stroke prevention measures n/a 0.51*
Controlled BP at 0 mo, % 68 66 1.03 (0.92 – 1.16) 0.60
Controlled BP at 6 mo, % 76 67 1.13 (1.02 – 1.25) 0.02
Change in % with controlled BP n/a 0.07*
Controlled LDL cholesterol at 0 mo, % 58 58 1.02 (0.88 – 1.16) 0.81
Controlled LDL cholesterol at 6 mo, % 54 58 0.95 (0.82 – 1.10) 0.46
Change in % with controlled LDL cholesterol n/a 0.30*
Taking anti-thrombotic at 0 mo, % 81 84 0.96 (0.89 – 1.04) 0.30
Taking anti-thrombotic at 6 mo, % 82 84 0.98 (0.91 – 1.06) 0.61
Change in % taking anti-thrombotic medication n/a 0.79*
Abbreviations: BP, blood pressure; CI, confidence interval; LDL, low-density lipoprotein
*Generalized estimating equations were used to estimate the likelihood of achieving controlled stroke prevention measures at 6-months in the 
intervention group as compared to the control group, after adjusting for control status at baseline. Significance tests are tests of the group × time 
interaction.
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